9 terminated. 9 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 9 |
| Phase 3 | 3 | Terminated 3 |
Follow Polymyositis: new trials by email Literature Review of Polymyositis trials Research Report on Polymyositis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of M5049 in DM and PM Participants (NEPTUNIA) M5049 dose, Placebo - Dermatomyositis, Polymyositis | Phase 2 | Terminated | EMD Serono Research & Development Institute, Inc. | 20 | 2023-01-19 | 2026-09-09 |
| Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis Ravulizumab, Placebo - Dermatomyositis | Phase 2 / Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 38 | 2021-11-19 | 2025-07-09 |
| COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders Moderna mRNA-1273, BNT162b2, Ad26.COV2.S - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 258 | 2021-08-13 | 2026-06-10 |
| Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis JBT-101, Placebo - Dermatomyositis | Phase 2 | Terminated | Corbus Pharmaceuticals Inc. | 22 | 2015-06-01 | 2023-01-19 |
| Safety and Efficacy of BAF312 in Dermatomyositis BAF312, Placebo - Active Dermatomyositis | Phase 2 | Terminated | Novartis Pharmaceuticals | 17 | 2013-08-25 | 2021-01-05 |
| Efficacy and Tolerability of BAF312 in Patients With Polymyositis Placebo, BAF312 - Polymyositis | Phase 2 | Terminated | Novartis Pharmaceuticals | 14 | 2013-04-24 | 2021-01-05 |
| A Clinical Trial for CTD-ILD Treatment N-Acetylcysteine - Interstitial Lung Disease, Connective Tissue Disease | Phase 2 / Phase 3 | Terminated | University of Michigan | 5 | 2011-12-01 | 2017-04-06 |
| Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis BAF312, Placebo - Polymyositis, Dermatomyositis | Phase 2 | Terminated | Novartis Pharmaceuticals | 18 | 2010-06-15 | 2019-04-25 |
| Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Prednisone, Methotrexate, Etanercept - Dermatomyositis | Phase 2 / Phase 3 | Terminated | Children's Hospital Medical Center, Cincinnati | 75 | 2002-08-01 | 2013-08-01 |
Dermatomyositis (8) · Myositis (3) · Arthritis, Rheumatoid (2) · Myositis, Inclusion Body (2) · Arthritis, Juvenile (1) · Autoimmune Diseases (1) · COVID-19 (1) · Connective Tissue Diseases (1) · Deglutition Disorders (1) · Exanthema (1) · Lung Diseases, Interstitial (1) · Lupus Erythematosus, Systemic (1) · Mixed Connective Tissue Disease (1) · Multiple Sclerosis (1)
Muscular Diseases (9) · Musculoskeletal Diseases (9) · Nervous System Diseases (9) · Neuromuscular Diseases (9) · Skin Diseases (8) · Skin and Connective Tissue Diseases (8) · Connective Tissue Diseases (7) · Myositis (6) · Arthritis (2) · Immune System Diseases (2) · Joint Diseases (2) · Lung Diseases (2) · Respiratory Tract Diseases (2) · Rheumatic Diseases (2)
siponimod (3) · Methotrexate (2) · 2019-nCoV Vaccine mRNA-1273 (1) · Acetylcysteine (1) · Ad26COVS1 (1) · BNT162 Vaccine (1) · BNT162b5 (1) · COVID-19 Vaccines (1) · Etanercept (1) · Mycophenolic Acid (1) · Prednisone (1) · lenabasum (1) · ravulizumab (1)
Novartis Pharmaceuticals (3) · Alexion Pharmaceuticals, Inc. (1) · Children's Hospital Medical Center, Cincinnati (1) · Corbus Pharmaceuticals Inc. (1) · EMD Serono Research & Development Institute, Inc. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Michigan (1)
United States (9) · Czechia (4) · Poland (3) · United Kingdom (3) · Hungary (2) · Italy (2) · Japan (2) · Spain (2) · Taiwan (2) · Australia (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Greece (1)
Amit Bar-Or, MD, FRCP (1) · Daniel J. Lovell, MD, MPH (1) · Dinesh Khanna, MBBS, MSc (1) · Judith A. James, MD, PhD (1) · Meggan C. Mackay, MD, MS (1) · Natasha Mckerran Ruth, MD (1) · Stacy Ardoin, MD (1) · Tracey Wright, MD (1) · Victoria Werth, M.D. (1) · Virginia Pascual, MD (1)
PMID 35490744, PMID 39403556, PMID 41289027
2008 (1), P60AR047784 (1), R21AR066286 (1)